Zacks Investment Research Lowers Corium International Inc. (CORI) to Sell
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
A number of other equities research analysts have also issued reports on CORI. Needham & Company LLC reiterated a buy rating and set a $15.00 target price on shares of Corium International in a report on Monday, September 26th. FBR & Co set a $18.00 target price on shares of Corium International and gave the stock a buy rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. Corium International presently has an average rating of Buy and an average price target of $11.92.
Corium International (NASDAQ:CORI) opened at 5.41 on Tuesday. The stock’s market cap is $120.96 million. Corium International has a 12-month low of $3.14 and a 12-month high of $9.93. The firm’s 50 day moving average price is $5.77 and its 200-day moving average price is $4.60.
Corium International (NASDAQ:CORI) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.08. Corium International had a negative net margin of 104.77% and a negative return on equity of 158.38%. Equities research analysts anticipate that Corium International will post ($1.62) earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Corium International by 1.6% in the first quarter. Geode Capital Management LLC now owns 76,871 shares of the biopharmaceutical company’s stock valued at $296,000 after buying an additional 1,187 shares in the last quarter. Opaleye Management Inc. raised its stake in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Corium International by 1.4% in the first quarter. Franklin Resources Inc. now owns 818,290 shares of the biopharmaceutical company’s stock valued at $3,158,000 after buying an additional 11,200 shares in the last quarter. RTW Investments LLC raised its stake in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 24,629 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of Corium International during the second quarter valued at approximately $152,000. Institutional investors and hedge funds own 88.15% of the company’s stock.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.